Table 3. Hazard ratios (HR) (95% CI) of venous thromboembolism for quintiles, per standard deviation decrement, and for very low (<5 percentile) baseline serum albumin levels, CHS, 1989-2002.
| Range (g/L) N |
HR (95% CI) per Albumin Quintile | HR (95% CI) per SD Decrement of Albumin (2.9 g/L) | HR(95% CI) for Bottom 5% of Albumin vs Top 95% | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Q1 28-37 1076 |
Q2 38-39 1330 |
Q3 40 742 |
Q4 41-42 1270 |
Q5 43-52 982 |
Trend p-value | ||||
| Total VTE | N events | 48 | 32 | 24 | 42 | 48 | 174 | 174 | |
| Model 1 | 1.50 (0.93, 2.41) | 0.81 (0.49, 1.34) | 1.16 (0.67, 2.00) | 1.15 (0.71, 1.85) | 1.00 | 0.38 | 1.12 (0.96, 1.31) | 1.85 (1.14, 3.00) | |
| Model 2 | 1.41 (0.87, 2.28) | 0.79 (0.47, 1.31) | 1.11 (0.64, 1.93) | 1.14 (0.71, 1.84) | 1.00 | 0.55 | 1.10 (0.94, 1.29) | 1.80 (1.11, 2.93) | |
| Model 3 | 1.33 (0.79, 2.24) | 0.78 (0.45, 1.35) | 1.01 (0.56, 1.83) | 1.21 (0.73, 1.98) | 1.00 | 0.89 | 1.07 (0.90, 1.27) | 1.84 (1.05, 3.21) | |
| Idiopathic VTE | N events | 16 | 11 | 10 | 16 | 12 | 65 | 65 | |
| Model 1 | 1.21 (0.56, 2.59) | 0.65 (0.29, 1.48) | 1.12 (0.48, 2.60) | 1.02 (0.48, 2.16) | 1.00 | 0.95 | 0.99 (0.77, 1.28) | 1.28 (0.51, 3.21) | |
| Model 2 | 1.10 (0.51, 2.39) | 0.62 (0.27, 1.41) | 1.07 (0.46, 2.50) | 0.99 (0.47, 2.10) | 1.00 | 0.77 | 0.96 (0.75, 1.24) | 1.20 (0.48, 3.03) | |
| Model 3 | 1.02 (0.46, 2.28) | 0.49 (0.20, 1.21) | 0.90 (0.36, 2.21) | 0.95 (0.44, 2.03) | 1.00 | 0.53 | 0.93 (0.70, 1.22) | 1.27 (0.46, 3.55) | |
| Secondary VTE | N events | 32 | 21 | 14 | 26 | 16 | 109 | 109 | |
| Model 1 | 1.72 (0.93, 3.19) | 0.92 (0.48, 1.77) | 1.18 (0.58, 2.43) | 1.25 (0.67, 2.33) | 1.00 | 0.24 | 1.20 (0.99, 1.47) | 2.23 (1.26, 3.94) | |
| Model 2 | 1.65 (0.89, 3.08) | 0.90 (0.47, 1.74) | 1.14 (0.55, 2.35) | 1.25 (0.67, 2.33) | 1.00 | 0.32 | 1.19 (0.98, 1.46) | 2.25 (1.27, 3.99) | |
| Model 3 | 1.60 (0.80, 3.18) | 1.02 (0.51, 2.07) | 1.10 (0.50, 2.44) | 1.42 (0.74, 2.74) | 1.00 | 0.51 | 1.17 (0.94, 1.45) | 2.30 (1.18, 4.50) | |
Model 1: Adjusted for age (continuous), sex, and race (African American, other)
Model 2: Adjusted for age (continuous), sex, and HRT use (3-level categorical variable), race, diabetes status (yes, no), history of cancer (yes, no), eGFR (continuous), and BMI (continuous)
Model 3: Adjusted for Model 2 + Factor VIII (continuous), aPTT (continuous), and fibrinogen (continuous)
Abbreviations: aPTT, activated partial thromboplastin time; BMI, body mass index; CHS, Cardiovascular Health Study; eGFR, estimated glomerular filtration rate; HR, hazard ratio; HRT, hormone replacement therapy; VTE, venous thromboembolism